Verve Therapeutics Provides Corporate Updates and Reports Se

09.08.2022 - Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025 Patient Dosing Underway with Lead Candidate, VERVE-101, for Treatment of Heterozygous Familial Hypercholesterolemia; Regulatory ...

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , New Zealand , John Evans , Jen Robinson , Alexanderg Bo Cumbo , Ashlea Kosikowski , Allison Dorval , Sekar Kathiresan , Eisai Corporation Of North America , Janssen Pharmaceuticals Inc , Nasdaq , Vertex Pharmaceuticals Incorporated , Verve Therapeutics Inc , Research Development Rd Expenses , European Society Of Cardiology , Sarepta Therapeutics Inc , Vertex Pharmaceuticals , Lexicon Pharmaceuticals , Gilead Sciences , Eisai Inc , Aavantibio Inc , Research Collaboration , Exchange Commission , Company Evolution , Johnson , Business Development , Vivogene Editing Program For Liver Disease , Join Board , Supporting Company , Dosing Initiated , Interim Clinical Data Anticipated , United States Anticipated , Second Half , Upcoming Data , Supporting Nomination , European Society , Enabling Studies , Vivogene Editing Program , Liver Disease , Pharmaceuticals Incorporated , Expand Pipeline , Provide Additional Operating Flexibility , Beam Therapeutics , Follow On Offering , Multiple Industry Veterans , Support Company , Lonnel Coats , Eisai Corporation , North America , Janssen Pharmaceuticals , Sarepta Therapeutics , Private Securities Litigation Reform Act ,